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Registration of drugs for treating cancer and HIV infection: a plea to 
carry out phase 3 trials before admission to the market
P P Koopmans
Drugs for cancer and HIV infection tend to be safety acceptable., marketing of the drug could be 
admitted to the market on the basis of results from approved early, Observations in a few patients or even
phase 2 trials. Assessing the benefit-risk balance a n »  *  * . . . — 1 trial” theoretically would suffice for registra-
with phase 2 trials often is difficult—the effect of the tion if the action of the drug is impressive. This
drug is usually temporary; the correlation between situation, however, is rare. Although several classes of
response or improvement of clinical measurements drugs have high “cure rates” (fluoroquinolones in
and the patient’s wellbeing is often poor; and the side urinary tract infections, omeprazole and H2-receptor
effects of drugs for these fatal diseases are serious, antagonists in peptic ulcer disease, for example), most
Therefore, although sometimes difficult to conduct, drug regulating authorities have not registered them
comparative trials that use standard treatment, without comparative trials.
placebos, or best supportive care remain the corner­
stone for reliably assessing the benefit-risk balance.
Should other criteria be applied in fatal diseases? My 
answer is no, because especially in cancers and HIV 
infection, the benefit:risk ratio is much more difficult
The common criterion of drug regulatory committees to assess than in other diseases, 
for registration of a drug is that efficacy and safety have
been shown in extensive pharmaceutical, pharmaco­
logical, toxicological, and clinical studies. Usually the Is treatment efficacious or beneficial?
clinical aspects of a drug are studied in phase 1,2, and 3 In cancer or HIV infection it is very difficult to
trials, but whether all three phases are necessary for the conclude whether a drug is efficacious or whether the 
registration of drugs for cancer and HIV infection is a treatment offers benefit to the patient. Most advanced
matter of debate in Europe and the United States. malignancies and HIV infection cannot yet be cured
The media, the pharmaceutical industry, and the with drug treatment. Mostly, the effect of the drugs is 
patients involved all put pressure on the drug temporary; and best, death is postponed.
regulatory authorities to accelerate the procedures and Cure is an unrealistic requirement for registration of
to relax the criteria for admitting oncolytics and drugs oncolytic agents or drugs used in HIV infection, and
against HIV infection to the market. They argue that the criteria for efficacy of these drugs have already been
the three phases of clinical trials are time consuming loosened. In the treatment of cancer the efficacy of
and may withhold a potentially valuable drug from the a drug is determined by the number of patients respond-
patient for too long, and that this requirement is ing (complete or partial disappearance of the tumour),
therefore not ethical. They advocate early registration duration of response, disease free interval, and the
if it appears from phase 2 trials that a tumor is increase in survival. The effect of any cytostatic drug
responding and the outcome of the patients is better depends on the nature and extent of the particular
than that of historical controls; for such drugs phase 3 malignancy, and in most advanced malignant diseases
trials, in which the drug is compared with standard only 25-30% of patients may respond to the drug.
treatment, placebo, or untreated controls, can be 
omitted or done after marketing. They also say that 
drugs for HIV infection should be available as soon as are clinically relevant depends on the definitions of
a com-
Survival, although better than in untreated patients, 
seldom exceeds one or two years. Whether these figures
possible—-for instance, if a 
surrogate end points has been shown.
influence on response, the proportion of patients t
plete response, and the implications of a complete 
In the United States and some European countries response in the course of the disease. Such figures 
the authorities tend to allow early registration of drugs should not be underestimated, but such percentages 
to treat fatal diseases and consider a positive outcome would be unacceptably low for registration of drug 
in phase 2 trials or a favourable effect on surrogate end treatments in many other diseases.
points sufficient to authorise marketing. An accelerated Examples are numerous: at present relatively low
approval may, however, come into conflict with the response percentages and a limited increase in survival
main task of the drug regulatory authorities: to assess can be achieved with registered treatments for
the benefit-risk ratio of a drug. In contrast with the malignancies of the gastrointestinal tract (5-fluoro-
prescribers and consumers, the authorities have the uracil for metastasised colon cancer),1 in head and neck
opportunity to review all the data on a drug, and thus cancer (cisplatin),! and non-small cell lung cancer,’
can give an impartial judgment about the balance of its renal cancer (recombinant interleukin 2),“ AIDS
benefits and risks. Since the community is aware of this related kaposi’s sarcoma (interferon alfa),1 and, more
impartial judgment and relies on it, early registration recently, paclitaxel tor cisplatin resistant ovarian
has the danger that false expectations are created about cancer.'1 The new purine analogue cladribine for hairy
the efficacy of the drug. cell leukaemia seems to be one of the exceptions,7 as in
Are randomised controlled trials always necessary phase 2 trials this drug looks far better than interferon
for a reliable assessment of the risk or benefit of a drug? alfa; administration is also more convenient for the
In some circumstances the answer could be no: if the patient and the safety profile is acceptable,
results of phase trials indicate that the efficacy is In HIV infection the most important measures of
unequivocal (a formerly fatal disease is cured) and the efficacy are the occurrence of AIDS related events,
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Hypothetical ( a) change in 
survival curve of cancer patients 
and (b) side effects induced by 
a new oncolytic drug, illustrating 
the difficulty of assessing the 
benefit-risk balance of a new drug 
for cancer investigated without 
a control group
the reference treatment depends on whether there is a 
standard treatment for the disease. If not—in patients 
with an advanced malignancy who have already 
received extensive treatment, or when the drug is used 
as second line treatment—the reference treatment 
should consist of placebo and best supportive care. 
Many supportive measures,H such as transfusions, 
haematopoietic growth factors, analgesics, antimicro­
bials, antiemetics, and even corticosteroids,15 may 
influence the quality of life favourably; best support­
ive care is therefore justified as reference treatment.
Such trials may be difficult to perform. The ethics of 
using a placebo arm in a fatal disease is disputed in 
some countries,1''17 and many physicians and patients 
survival, and the course of surrogate measures (CD4 will be reluctant to participate because of high (often 
counts, virus RNA, p24 antigen). The therapeutic gain unrealistic) expectations of new drugs. One solution 
of the currently marketed antiretrovirus drugs is would be to incorporate patients’ preferences in the 
limited.* The increased survival of patients with AIDS randomisation.18 A comparison with historical controls 
taking zidovudine, a drug that was compared with may seem easier to perform, but problems arise in
interpreting results—in particular, there may be 
differences in patient characteristics, criteria for
placebo, is temporary and relatively short lasting.
Didanosine and zalcitabine are registered in several 
countries for treating patients with AIDS who cannot response, accuracy in the disease staging, and the use 
tolerate zidovudine or no longer respond to it, but it is of supportive measures and drugs.19
doubtful whether morbidity and survival are greatly Placebo controlled trials might be avoided by
improved. These drugs were admitted to the market performing carefully designed dose finding studies, 
mainly because of their favourable effect on surrogate looking for the dosage that has the lowest toxicity but is
measures, but it has become clear that such an effect is 
poorly correlated with clinical outcom e.10
T oxic effects
still effective. These trials are not easy to perform with 
cytotoxic drugs or antimicrobial drugs. Dosage of 
a cytotoxic drug is often based on the maximum 
tolerable dosage (found in phase 1 studies) and that of 
antimicrobial drugs comes from in vitro susceptibility
The second reason why benefit is more difficult to studies.
assess for oncolytic treatment and in HIV infection is 
that the drugs are often toxic; neutropenia, gastro­
intestinal side effects, alopecia, mucositis, neuropathy, 
or (in case of didanosine) the risk of pancreatitis, as
Conclusions
In cancer, HIV infection, and possibly other fatal
well as frequent hospital admissions for complications diseases, comparative trials either with placebo or with
of treatment (such as infectious episodes and the need best supportive care seem to be inevitable for a reliable
for blood transfusions), may affect the quality of life of assessment of the benefit-risk ratio. The drug
the patient and should be set against the temporary regulating authorities could themselves be helpful in
effect. Furthermore, the action of a particular drug is 
harder to interpret when more than one cytotoxic drug 
is given or when antimicrobial agents are also used.
making clear to the public that, especially in these 
diseases, such trials, although time consuming, 
the best guarantee against drugs being registered too
Of course, one also cannot conclude automatically early and possibly being a disappointment afterwards.
that a drug with a limited effect, which prolongs life 
only slightly and possesses many side effects, is not 
valuable for a patient. For instance, the detrimental 
impact of the side effects of chemotherapy for 
advanced breast or colon cancer on the quality of life of 
cancer patients seems to be less than expected.1112 
These data cannot, however, be generalised to all cyto­
static treatments.
Whether the treatment is beneficial depends on the 
definitions of response. When response is correlated 
with benefit or obvious palliation, improvement of the 
patient’s general condition, or improvement in 
symptoms, this should be taken into account. Particu­
larly in phase 2 trials, however, either this is not the 
case or the correlation between response and clinical 
symptoms is vague.
Wellbeing of the patient
Before a marketing authorisation is delivered, 
studies of the impact of the treatment on the patient’s 
wellbeing should be required. One approach is to 
investigate the influence of the drug on simple clinical 
symptoms or laboratory markers associated with the 
malignant disease or HIV infection (fatigue, body 
weight, pain, dyspnoea, anaemia, anorexia, etc); 
another is to formally assess quality of life with 
validated questionnaires.”
Comparative trials seem most appropriate, as the 
absence of a control group makes a reliable assessment
(figure)
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